Company: ImStar Therapeutics
Drug Type: Small Molecule
Mechanism Type: Proteostasis, Protein misfolding modulator
Mechanism: IMS-088 is a novel compound derived from withaferin A, a natural compound isolated from the leaves of the winter cherry plant, with improved pharmacological properties for a therapeutic drug. Studies in the SOD1 mouse model of ALS have shown that presymptomatic treatment with withaferin A prolongs survival in this model and reduces misfolded SOD1 levels. A subsequent analysis suggests this reduction may be due to, upon treatment, an increase in heat shock protein 25 (a mouse ortholog of heat shock protein 27).
U.S. Status for ALS: Preclinical
 ImStar Therapeutics. Pipeline. ImStar Therapeutics, n.d. Accessed 9 Mar 2016 from http://imstartx.com/pipeline.html
 Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Patel, P et al. Neurotherapeutics 2015 Jan;12(1):217-33.
Last updated March 9th, 2019